Business Description
Bio-Rad Laboratories Inc
NAICS : 334516
SIC : 3826
ISIN : US0905722072
Share Class Description:
FRA:BUWA: Class ATotal Employee Number:
7,450Description
Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 1.18 | |||||
Equity-to-Asset | 0.7 | |||||
Debt-to-Equity | 0.19 | |||||
Debt-to-EBITDA | 2.41 | |||||
Interest Coverage | 4.6 | |||||
Piotroski F-Score | 5/9 | |||||
Altman Z-Score | 3.56 | |||||
Beneish M-Score | -2.71 | |||||
WACC vs ROIC | ||||||
Growth Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | 0.2 | |||||
3-Year EPS without NRI Growth Rate | -11.7 | |||||
3-Year FCF Growth Rate | 72.2 | |||||
3-Year Book Growth Rate | -5.3 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 4.69 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 2.09 |
Momentum Rank
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 62.52 | |||||
9-Day RSI | 68.65 | |||||
14-Day RSI | 68.92 | |||||
3-1 Month Momentum % | 23.65 | |||||
6-1 Month Momentum % | 20.84 | |||||
12-1 Month Momentum % | 6.55 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 3.14 | |||||
Quick Ratio | 2.33 | |||||
Cash Ratio | 1.68 | |||||
Days Inventory | 227.05 | |||||
Days Sales Outstanding | 63.81 | |||||
Days Payable | 39.49 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | 3 | |||||
Shareholder Yield % | 1.43 |
Profitability Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 51.9 | |||||
Operating Margin % | 8.67 | |||||
Net Margin % | 8.59 | |||||
EBITDA Margin % | 21.93 | |||||
FCF Margin % | 13.62 | |||||
OCF Margin % | 19.01 | |||||
ROE % | 3.15 | |||||
ROA % | 2.2 | |||||
ROIC % | 1.73 | |||||
3-Year ROIIC % | 7.53 | |||||
ROC (Joel Greenblatt) % | 24.77 | |||||
ROCE % | 4.24 | |||||
Years of Profitability over Past 10-Year | 7 | |||||
Moat Score | 6 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PE Ratio | 43.18 | |||||
Forward PE Ratio | 36.95 | |||||
PE Ratio without NRI | 40.51 | |||||
Shiller PE Ratio | 16.02 | |||||
Price-to-Owner-Earnings | 25.3 | |||||
PS Ratio | 3.71 | |||||
PB Ratio | 1.33 | |||||
Price-to-Tangible-Book | 1.48 | |||||
Price-to-Free-Cash-Flow | 27.18 | |||||
Price-to-Operating-Cash-Flow | 19.48 | |||||
EV-to-EBIT | 23 | |||||
EV-to-Forward-EBIT | 27 | |||||
EV-to-EBITDA | 16.17 | |||||
EV-to-Forward-EBITDA | 20.13 | |||||
EV-to-Revenue | 3.55 | |||||
EV-to-Forward-Revenue | 3.59 | |||||
EV-to-FCF | 26 | |||||
Price-to-GF-Value | 1.13 | |||||
Price-to-Projected-FCF | 1.08 | |||||
Price-to-Median-PS-Value | 0.96 | |||||
Price-to-Graham-Number | 1.63 | |||||
Earnings Yield (Greenblatt) % | 4.35 | |||||
FCF Yield % | 3.75 | |||||
Forward Rate of Return (Yacktman) % | 22.77 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Bio-Rad Laboratories Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 2,225.583 | ||
| EPS (TTM) (€) | 7.05 | ||
| Beta | 1.5037 | ||
| 3-Year Sharpe Ratio | -0.14 | ||
| 3-Year Sortino Ratio | -0.19 | ||
| Volatility % | 32.89 | ||
| 14-Day RSI | 68.92 | ||
| 14-Day ATR (€) | 8.389688 | ||
| 20-Day SMA (€) | 289.66 | ||
| 12-1 Month Momentum % | 6.55 | ||
| 52-Week Range (€) | 204.6 - 312.4 | ||
| Shares Outstanding (Mil) | 26.74 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 5 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Bio-Rad Laboratories Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Bio-Rad Laboratories Inc Stock Events
| Event | Date | Price (€) | ||
|---|---|---|---|---|
| Fourth quarter earnings conference call for 2026 | 2027-02-12 17:00 | In 179 days | ||
| Annual report for 2026 | 2027-02-12 | In 178 days | ||
| Fourth quarter earnings results for 2026 | 2027-02-12 | In 178 days | ||
| Third quarter earnings conference call for 2026 | 2026-10-29 17:00 | In 73 days | ||
| Third quarter earnings results for 2026 | 2026-10-29 | In 72 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-04 17:00 | 290.40 (+3.12%) | ||
| Second quarter earnings results for 2026 | 2026-08-04 | 290.40 (+3.12%) | ||
| Guidance call for 2026 | 2026-06-03 08:45 | 263.00 (+1.23%) | ||
| Guidance call for 2026 | 2026-05-19 08:30 | 242.00 (+7.56%) | ||
| First quarter earnings conference call for 2026 | 2026-04-30 17:30 | 235.60 (-0.84%) |
Show
Entries
Bio-Rad Laboratories Inc Frequently Asked Questions
What is Bio-Rad Laboratories Inc(FRA:BUWA)'s stock price today?
The current price of FRA:BUWA is €307.20. The 52 week high of FRA:BUWA is €312.40 and 52 week low is €204.60.
When is next earnings date of Bio-Rad Laboratories Inc(FRA:BUWA)?
The next earnings date of Bio-Rad Laboratories Inc(FRA:BUWA) is 2026-10-29 Est..
Does Bio-Rad Laboratories Inc(FRA:BUWA) pay dividends? If so, how much?
Bio-Rad Laboratories Inc(FRA:BUWA) does not pay dividend.
Press Release
Articles on Bio-Rad Laboratories Inc
No articles.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers